| Literature DB >> 31533032 |
Tianqi Leng1, Hossain Delowar Akther2, Carl-Philipp Hackstein2, Kate Powell3, Thomas King1, Matthias Friedrich4, Zoe Christoforidou5, Sarah McCuaig4, Mastura Neyazi4, Carolina V Arancibia-Cárcamo5, Joachim Hagel1, Fiona Powrie4, Raphael Sanches Peres4, Val Millar6, Daniel Ebner6, Rajesh Lamichhane7, James Ussher7, Timothy S C Hinks8, Emanuele Marchi1, Chris Willberg1, Paul Klenerman9.
Abstract
MAIT cells are an unconventional T cell population that can be activated through both TCR-dependent and TCR-independent mechanisms. Here, we examined the impact of combinations of TCR-dependent and TCR-independent signals in human CD8+ MAIT cells. TCR-independent activation of these MAIT cells from blood and gut was maximized by extending the panel of cytokines to include TNF-superfamily member TL1A. RNA-seq experiments revealed that TCR-dependent and TCR-independent signals drive MAIT cells to exert overlapping and specific effector functions, affecting both host defense and tissue homeostasis. Although TCR triggering alone is insufficient to drive sustained activation, TCR-triggered MAIT cells showed specific enrichment of tissue-repair functions at the gene and protein levels and in in vitro assays. Altogether, these data indicate the blend of TCR-dependent and TCR-independent signaling to CD8+ MAIT cells may play a role in controlling the balance between healthy and pathological processes of tissue inflammation and repair.Entities:
Keywords: MAIT cells; TCR signaling; cytokines; effector functions; tissue repair
Mesh:
Substances:
Year: 2019 PMID: 31533032 PMCID: PMC6899450 DOI: 10.1016/j.celrep.2019.08.050
Source DB: PubMed Journal: Cell Rep Impact factor: 9.995
Figure 1TL1A Enhances the Activation of MAIT Cells Suboptimally Stimulated with IL-12 and IL-18
CD8+ T cells were enriched from healthy peripheral blood mononuclear cells (PBMCs) and stimulated overnight with different combinations of cytokines: IL-12 at 2 ng/mL, IL-18 at 50 ng/mL, IL-15 at 25 ng/mL, and TL1A from 0.01 to 100 ng/mL as indicated.
(A–C) Proportions of CD8+ MAIT/CD161+ or CD161− cells producing IFN-γ (A), TNF-α (B), or CD69 (C) following overnight stimulation with suboptimal concentrations of IL-12 and IL-18, plus varying concentrations of TL1A.
(D) Representative histograms showing the expression of IFN-γ, TNF-α, GrB, and CD69 by MAIT cells after stimulation with different combinations of cytokines.
(E–H) Frequency of MAIT cells expressing IFN-γ (E), TNF-α (F), GrB (G), and CD69 (H) upon stimulation with the indicated cytokines.
Data were acquired from seven donors in 2–3 experiments. Error bars represent means ± SEM. Differences among conditions were analyzed by Friedman tests with Dunn’s multiple comparison tests. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.
See also Figure S1.
Figure 2TCR and Cytokine Signaling Combine to Promote MAIT Cell Effector Functions
(A–J) Magnetic-activated cell sorting (MACS)-enriched CD8 T cells from the blood were cultured overnight in the presence of the indicated cytokines, together with the THP1 cell pulsed with DMSO or the MAIT-antigen 5-OP-RU (A–E) or with αCD3/CD28 beads (F–J).
(A) Representative histograms showing the expression of IFN-γ, TNF-α, GrB, and CD69 by MAIT cells after stimulation with different cytokines in the presence of 5-OP-RU.
(B–E) Frequency of MAIT cells expressing IFN-γ (B), TNF-α (C), GrB (D), or CD69 (E) upon stimulation with the indicated cytokines.
(F) Representative histograms showing the expression of IFN-γ, TNF-α, GrB, and CD69 by MAIT cells after stimulation with different cytokines in the presence of 5-OP-RU.
(G–J) Frequency of MAIT cells expressing IFN-γ (G), TNF-α (H), GrB (I), or CD69 (J) upon stimulation with the indicated cytokines.
Data were acquired from seven donors in two experiments. Error bars represent means ± SEM. Differences among conditions were analyzed by Friedman tests with Dunn’s multiple comparison tests. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.001.
See also Figure S2.
Figure 3Gut-Derived MAIT Cells Show a Broadly Similar Response Pattern toward Innate and Adaptive Stimuli Compared with Their Blood-Derived Counterparts
Representative plots showing the percentage of cells positive for the indicated effector molecules as a proportion of CD8+ MAIT cells.
(A–C) Proportions of blood-derived (n = 32) CD8+ MAIT cells producing IFN-γ (A), TNF-α (B), or GrB (C) following overnight stimulation with combinations of suboptimal concentrations of IL-12 and IL-18, TL1A, and αCD3/CD28 beads as indicated.
(D–F) Proportions of gut-derived (n = 13) CD8+ MAIT cells producing IFN-γ (D), TNF-α (E), or GrB (F) stimulated in the same way as in (A)–(C).
(G and H) Expression of IFN-γ, TNF-α, and GrB by blood-derived (G, n = 7) or gut-derived (H, n = 6) CD8+ MAIT cells 20 h after coculture with THP1 cells alone or THP1 cells incubated with 25 fixed E. coli bacteria per cell.
Data were acquired from multiple donors as indicated in 3–5 experiments. Error bars represent means ± SEM. Differences among conditions were analyzed by Friedman tests with Dunn’s multiple comparison tests (A–F), two-way ANOVA (G), or Wilcoxon tests (H). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.001.
See also Figure S3.
Figure 4TCR- and Cytokine-Activated MAIT Cells Possess Distinct Transcriptional Profiles
(A–C) Venn diagrams showing genes that are significantly differentially modulated (p < 0.05, fold change > 4) in TCR (T)-, cytokine (C)-, or TCR and cytokine (TC)-treated CD8+ MAIT cells compared with untreated (UT) MAIT cells of three healthy individuals. The cytokine (C) stimulation consisted of a cocktail of 4 cytokines: IL-12 (2 ng/mL), IL-18 (50 ng/mL), IL-15 (25 ng/mL), and TL1A (100 ng/mL). Genes with significantly altered expression levels (A) are divided into two sets: those are that are upregulated upon stimulation (B) and those that are downregulated upon stimulation (C).
(D) Heatmap showing 1,594 significantly differentially expressed transcripts (p < 0.05, fold change > 4) between TCR/C/TC-stimulated and UT CD8+ MAIT cells among the same three healthy individuals.
(E) Visualization of the CD8+ MAIT cell transcripts elicited by differential stimulations in the subspace of the first principle components (PCs). Each colored circle represents a sample and is color coded in accordance with the conditions with which cells were stimulated, as illustrated on the right-hand side of the graph.
(F–K) Volcano plots to visualize differentially expressed transcriptional profiles of activated CD8+ MAIT cells stimulated in different ways. Each point represents a single gene, and genes expressed at significantly higher or lower levels between the compared conditions are depicted, respectively, in the upper-right or upper-left corner of each plot. Genes discussed in the text are highlighted in blue (tissue repair associated) or in red (inflammation associated). The gene expression of untreated MAIT cells was compared to (F) T-, (G) C-, or (H) TC-stimulated MAIT cells. Further, gene expression in those cells was also compared directly between the different stimulation conditions: (I) T- to C- stimulation, (J) T- to TC-stimulation, and finally (K) C- to TC-stimulation.
Data were acquired from three donors in one experiment.
See also Figure S4 and Tables S1, S2, and S3.
Figure 5TCR-Mediated Activation of MAIT Cells Leads to the Expression of Tissue-Repair-Associated Molecules and Accelerates Wound Healing
(A–C) Gene set enrichment summary plots for stimulated sorted MAIT cell-versus-unstimulated cell-ranked genes. Depicted are the individual plots for TCR-stimulated versus UT in (A), TC-stimulated versus UT in (B), and C versus unstimulated in (C). Non-significant for C versus UT, normalized enrichment score (NES) = 1.63; p < 0.0002 for TCR versus UT, NES = 1.57; and p < 0.0002 for TC versus UT. Data were acquired from three donors in one experiment.
(D) Flow cytometry analysis of the expression of TNF-α, furin, and CCL3 by CD161++/MAIT CD8+ T cells in response to fixed E. coli presented by THP1 cells in the presence or absence of an anti-MR1 (αMR1) blocking antibody at the 72-h time point.
(E) Statistical analysis of the expression of the effector molecules shown in (D).
(F) Caco2 cells were grown to confluency and scratched with a WoundMaker device to perform in vitro wound-healing assays. Cells were supplemented with different supernatants collected from 72-h cocultures of enriched CD8 T cells with E. coli-loaded THP1 cells in the presence or absence of αMR1, as indicated. The open wound areas were quantified as percentages of the initial wound size in the Caco2 cultures. Data points are mean ± SEM and were acquired from five biological replicates in two experiments.
(G) Representative pictures of the closure of the wounds in Caco2 cultures treated as in (F) were assessed with time-lapse imaging over a time course of 36 h. Data were acquired from seven donors in three experiments.
Differences among conditions were analyzed by two-way ANOVA. ns, not significant; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗∗p < 0.001. Scale bars, 250 μm.
See also Figure S5 and Table S3.
Figure 6Integrated Transcriptional Analyses Reveal the Relationship between In Vitro-Activated Human MAIT Cells and In Vivo-Activated Murine MAIT and Tc17 Cells
Hierarchical clustering analysis of the transcriptomic profiles of the indicated cell populations is shown. Similarity between the expression profiles is measured using a Euclidean distance (height). Datasets were derived from ImmGen (Heng et al., 2008), Linehan et al. (2018), and Hinks et al. (2019) and were integrated as described in the STAR Methods section. The relevant datasets are colored. UT, TCR, C, and TC refer to the conditions used in this paper on in vitro-activated human CD8+ MAIT cells (blue). Topical Tc17 and H2M3_CD8_SLO refer to the H2M3-restricted populations identified in Linehan et al. (2018) in the skin and secondary lymphoid organs of mice, respectively (red). The cells described in Hinks et al. (2019) are marked in yellow (stimulated human MAIT cells) or green (chronic or acute, derived during a late or an early time point after L. longbeachae infection in mice, respectively). See also Figure S6.
Figure 7MAIT Cells Can Be Found Close to and within the Colonic Epithelium
(A–G) Representative images showing the expression of Va7.2, CD161, CD8, PLZF, CD3, and CD103 in the lamina propria and the epithelium of fixed samples of colonic polyp tissue. Samples were mounted on cytometer chips and iteratively stained with sets of three directly fluorochrome-conjugated antibodies as described in the methods section. Depicted are a merged picture (A) and all the individual stains for Va7.2 (B), CD161(C), CD8 (D), PLZF (E), CD3 (F), and CD103 (G). White arrows mark cells showing co-expression of Va7.2, CD161, PLZF, and CD3 that were defined as MAIT cells here. Note that while CD8 was co-expressed in most of them, CD8− MAITs (arrow + asterisk) could also be found. In contrast, CD103 was rarely co-expressed on MAITs (arrow + diamond). During the iterative staining process dust particles and other detritus can be picked up by the solution flowing over the tissue creating autofluorescent artifacts (1–4). While some of these get washed away after completion of the staining cycle (1, 4), others present during multiple imaging rounds (2, 3). Scale bars, 50μm.
| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---|---|---|
| LEAF-purified mouse anti-human CD3 (clone UCHT1) | Biolegend | Discontinued Alternative: Cat# 300438; RRID: |
| LEAF-purified mouse anti-human CD28 (clone CD28.2) | Biolegend | Cat# 302914; RRID: |
| LEAF-purified mouse anti mouse/rat/human MR1 (clone 26.5) | Biolegend | Cat# 361103; RRID: |
| Anti-human CD3 (clone UCHT1) PerCp/Cy.5 | Biolegend | Cat# 300428; RRID: |
| Anti-human CD3 (clone OKT3) eFluor450 | eBioScience | Cat# 48-0037-42; RRID: |
| Anti-human CD3 (clone OKT3) BV605 | Biolegend | Cat# 317321; RRID: |
| Anti-human CD4 (clone M-T466) VioGreen | Miltenyi | Cat# 130-113-259; RRID: |
| Anti-human CD4 (clone OKT4) PerCP/Cy5.5 | eBioScience | Cat# 45-0048-42; RRID: |
| Anti-human CD8 (clone SK1) FITC | Biolegend | Cat# 344704; RRID: |
| Anti-human CD8 (clone REA734) VioGreen | Miltenyi | Cat# 130-110-684; RRID: |
| Anti-human CD8 (clone REA734) PE-Vio770 | Miltenyi | Cat# 130-110-680; RRID: |
| Anti-human CD39 (clone A1) PE | Biolegend | Cat# 328207; RRID: |
| Anti-human CD69 (clone H1.2F3) eFluor450 | eBioScience | Cat# 48-0691-82; RRID: |
| Anti-human CD103 (Ber-ACT8) PE | Biolegend | Cat# 350206; RRID: |
| Anti-human CD161 (clone 191B8) APC | Miltenyi | Cat# 130-113-590; RRID: |
| Anti-human CD161 (clone 191B8) PE | Miltenyi | Cat# 130-113-593; RRID: |
| Anti-human CD161 (clone 191B8) PE-Vio770 | Miltenyi | Cat# 130-113-594; RRID: |
| Anti-human CCL3/(4) (clone 93342) APC | R&D Systems | Cat# AF270NA; RRID: |
| Anti-human Furin (clone 222722) AF647 | R&D Systems | Cat# IC1503R-100UG; |
| Anti-human GM-CSF (clone BVD2-21C11) PerCP/Cy5.5 | Biolegend | Cat# 502312; RRID: |
| Anti-human GrB (clone GB12) APC | Initrogen | Cat# MHGB05; RRID: |
| Anti-human GrB (clone GB11) AF700 | BD BioSciences | Cat# 561016; RRID: |
| Anti-human IFNγ (clone 4S.B3) AF700 | Biolegend | Cat# 502520; RRID: |
| Anti-human IFNγ (clone 45-15) FITC | Miltenyi | Cat# 130-091-641; RRID: |
| Anti-human IFNγ (clone 4S.B3) PE/Cy7 | Biolegend | Cat# 502528; RRID: |
| Anti-human IgG2bκ (clone 133303) AF647 | R&D Systems | Cat# IC0041R; RRID: |
| Anti-human PD-1 (clone EH12.2H7) BV421 | Biolegend | Cat# 329920; RRID: |
| Anti-human/mouse PLZF (clone R17-809) PE | BD Pharmigen | Cat# 564850; RRID: |
| Anti-human TNFα (clone Mab11) FITC | Biolegend | Cat# 502906; RRID: |
| Anti-human TNFα (clone Mab11) PerCP/Cy5.5 | Biolegend | Cat# 502926; RRID: |
| Anti-human Vα7.2 (clone 3C10) APC | Biolegend | Cat# 351708; RRID: |
| Anti-human Vα7.2 (clone 3C10) FITC | Biolegend | Cat# 351704; RRID: |
| Anti-human Vα7.2 (clone 3C10) PE | Biolegend | Cat# 351710; RRID: |
| Anti-human Vα7.2 (clone 3C10) PE/Cy7 | Biolegend | Cat# 31712; RRID: |
| Anti-human TCRγ/δ (clone IMMU510) FITC | Beckman Coulter | Cat# IM1571U; |
| Anti-human TCRγ/δ (clone 11F2) APC-Vio770 | Miltenyi | Cat# 130-113-501; RRID: |
| Invitrogen | Cat# 18265017 | |
| Leukocyte cones | NHS Blood and Transplant | |
| Patient-derived resections (CRC) | TGU Biobank | |
| Patient-derived resection (IBD) | TGU Biobank | |
| Brefeldin A solution (1000X) | eBioScience | Cat# 00-4506-51 |
| 5-OP-RU | Fairlie group, | N/A |
| Collagenase A | Roche (mft)/ Merck | Cat# 10103578001 |
| DNase I | Roche (mft)/ Merck | Cat# 11284932001 |
| SuperScript III Reverse Transcriptase | Invitrogen | Cat# 18080093 |
| Human IL-12, premium grade | Miltenyi | Cat# 130-096-705 |
| Human IL-15, premium grade | Miltenyi | Cat# 130-095-764 |
| Recombinant Human IL-18 | MBL | Cat# B001-5 |
| Recombinant Human TL1A/TNFSF15 | R&D Systems | Cat# 1319-TL-010 |
| T cell Activation/Expansion Kit, human | Miltenyi | Cat# 130-091-441 |
| RNeasy Micro Kit | Quiagen | Cat# 74004 |
| LIVE/DEAD Fixable Near IR Dead Cell Stain Kit | Invitrogen | Cat# L10119 |
| Permeabilization buffer (10x) | eBioScience | Cat# 00-8333-56 |
| CD8 MicroBeads, human | Miltenyi | Cat# 130-045-201 |
| RNA-seq files (UT, T, C, CT) | This Paper | GEO |
| THP-1 | ATCC | TIB-202; RRID: CVCL 0006 |
| Caco2 | ATCC | HTB-37; RRID: CVCL 0025 |
| Primer specific for | Roche | N/A |
| Primer specific for | Roche | N/A |
| Primer specific for | Roche | N/A |
| Primer specific for | Roche | N/A |
| Primer specific for | Roche | N/A |
| Primer specific for | Roche | N/A |
| Bioinformatics & Evolutionary Genomics | Ghent University | |
| FlowJo 10 | Tree Star | |
| GSEA version 3.0 | ||
| Heatmapper | Wishart group, University of Alberta | |
| ImageJ Version 1.8 | NIH | |
| Partek Flow | Partek | |
| Prism Version 6.0b | Graphpad | |
| ZellExplorer | Zellkraftwerk GmbH | |
| 5-OP-RU-MR1-Tetramer PE | NIH tetramer core facility | N/A |
| PerColl | GE Healthcare (mft)/ Merck | Cat# GE17-0891-01 |
| Human | Thermo Fisher Scientific | Hs00218189_m1 |
| TaqMan Fast Advanced Master Mix | Thermo Fisher Scientific | Cat# 4444557 |
| Zellsafe Tissue chips | Zellkraftwerk GmbH | no. 28050606/02-010 |
| CRC patients | n = 21 |
|---|---|
| Age (Average, SD | 68, 12 |
| Sex (Male/Female) | 12/9 |
| Uninflamed, tumor-free tissue origin | |
| Small intestine | 0 |
| Large intestine | 21 |
| Time since diagnosis (years) | 1, 1 |
| Average, SD |
SD: standard deviation